New research based on decades of satellite observations reveals an unexpected atmospheric connection: mineral dust from distant deserts can trigger the freezing of clouds in the Northern Hemisphere. A new study has found that tiny dust particles traveling from distant deserts can help trigger the freezing of clouds in the Northern Hemisphere. This subtle atmospheric […]
Read more about this post…
Credits: Source
Disclaimer
Desert Dust Is Freezing Clouds Across the Northern Hemisphere – Science News
Scientists Solve a Long-Standing Chemistry Challenge With Light-Driven Catalysis – Science News
Chemists have developed a light-driven method for producing a rare and highly strained molecular structure known as “housane.” Designing a new drug often starts with a basic but difficult task: making the exact molecular framework needed for a medicine to work. Some important drugs, including penicillin, depend on tiny ring-shaped structures made from three or […]
Read more about this post…
Credits: Source
Disclaimer
Application for a tenure-track faculty position job with The Hebrew University – (Jobs)
The Institute of Biomedical and Oral Research (IBOR), Faculty of Dental Medicine of the Hebrew University, is pleased to announce a call for application that will be available starting October 2025, for a tenure track position.
The IBOR is a multi-disciplinary center comprising basic and clinical researchers in a wide range of medicine and dentistry-related research fields. Applicants are required to have Ph.D., Ph.D.- D.M.D., or Ph.D.-M.D. degrees, and postdoctoral training.
Candidates from a broad range of disciplines are encouraged to apply, however candidates who are computational biologists or bioinformaticians are actively sought in this cycle of recruitment.
Candidates are expected to develop independent research in a bio-medicine related fields, and to actively participate in the preclinical teaching program of the faculty.
Evaluation of candidates will be based primarily on academic excellence, originality of research, and the candidate’s potential to develop an outstanding independent research program.
Applications are on-line at the following website: http://ttp.huji.ac.il
For questions and inquiries: Mrs. Sigal Zaharan Committee coordinator The Institute of Biomedical and Oral Research (IBOR) Faculty of Dental Medicine Hebrew University of Jerusalem Email: sigalz@savion.huji.ac.il
Read more about this position…
Credits: Source
Disclaimer
TRACKing the tissue-specific origins of diverse effector T cell functions – Immunology Research
Nature Immunology, Published online: 12 March 2026; doi:10.1038/s41590-026-02475-w
A dual-recombinase fate-mapping system enables the permanent labeling of T cells activated during a treatment window, providing insights into the site-specific acquisition of diverse effector functions acquired at different antigen-priming sites.
Read more about this post…
Credits: Source
Disclaimer
A Subtle Twist in the Universe’s Oldest Light May Be Larger Than We Thought – Science News
Researchers created a technique to reduce uncertainty in cosmic birefringence measurements, resolving a key phase ambiguity and improving future studies of fundamental physics. A research team examining the uncertainties linked to cosmic birefringence has introduced a technique that improves the reliability of observational measurements. Their findings were reported in a study published in Physical Review […]
Read more about this post…
Credits: Source
Disclaimer
Professor of Integrated Immunology job with ETH Zurich – (Jobs)
The Department of Biology (D-BIOL; www.biol.ethz.ch) at ETH Zurich invites applications for the above-mentioned position.
The new professor will establish and lead an independent, internationally competitive research program in molecular immunology, with a potential for therapeutic translation. The professorship focuses on understanding how the immune system interacts with diverse tissue environments, using higher eukaryotic model organisms and approaches that are directly relevant to human disease.
Research programs may address innate and/or adaptive immune responses in contexts such as tissue damage caused by microbial infection, autoimmunity, mechanical injury, cancer, and inflammatory or degenerative diseases. Scholars working across the broad spectrum of immune biology, including those employing complex, heterogeneous experimental systems, are particularly encouraged to apply.
Commitment to an independent and timely teaching program is expected at the undergraduate (in German and English) and graduate (in English) level. The professorship will strengthen the curriculum of D-BIOL in the fundamental and concept lectures in the areas of immunology and disease mechanisms.
The professorship will be embedded in the Institute of Molecular Health Sciences, a vibrant and highly interdisciplinary biomedical research environment. The Institute and Department offer exceptional opportunities for collaboration, with strong expertise in tissue remodeling and regeneration, molecular oncology, genome engineering, functional genomics, metabolomics, and computational biology, providing an ideal setting for impactful and cross-disciplinary research.
ETH Zurich is an equal opportunity and family-friendly employer, values diversity, and is responsive to the needs of dual-career couples.
Please apply online: www.facultyaffairs.ethz.ch
Applications should include a curriculum vitae; a list of publications; three statements on a) research, b) teaching, c) leadership; descriptions of the three most important achievements; and a certificate of the highest degree. The letter of application should be addressed to the President of ETH Zurich, Prof. Dr. Joël Mesot. The closing date for applications is 30 April 2026.
Read more about this position…
Credits: Source
Disclaimer
A Cambridge Lab Mistake Reveals a Powerful New Way to Modify Drug Molecules – Science News
A surprising lab discovery reveals a light-powered way to tweak complex drugs faster, cleaner, and later in development. Researchers at the University of Cambridge have created a new technique for altering complex drug molecules using light instead of hazardous chemicals. The advance could speed up drug development and improve how medicines are produced. The work, […]
Read more about this post…
Credits: Source
Disclaimer
A clinic-responder-derived defined microbial consortium enhances anti-PD-1 immunotherapy efficacy in mice – Microbiology Research
Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).
Robert, C. et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384, 1109–1117 (2014).
Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 20, 1370–1385 (2019).
Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).
Bagchi, S., Yuan, R. & Engleman, E. G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol. 16, 223–249 (2021).
Topalian, S. L. et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol. 5, 1411–1420 (2019).
Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158–168 (2018).
Vetizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079–1084 (2015).
Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084–1089 (2015).
Jin, Y. et al. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC. J. Thorac. Oncol. 14, 1378–1389 (2019).
Derosa, L. et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann. Oncol. 29, 1437–1444 (2018).
Pinato, D. J. et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 5, 1774–1778 (2019).
Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).
Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018).
Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104–108 (2018).
Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602–609 (2020).
Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595–602 (2021).
Fernandes, M. R., Aggarwal, P., Costa, R. G. F., Cole, A. M. & Trinchieri, G. Targeting the gut microbiota for cancer therapy. Nat. Rev. Cancer 22, 703–722 (2022).
Simpson, R. C., Shanahan, E. R., Scolyer, R. A. & Long, G. V. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 20, 697–715 (2023).
Lee, K. A., Shaw, H. M., Bataille, V., Nathan, P. & Spector, T. D. Role of the gut microbiome for cancer patients receiving immunotherapy: dietary and treatment implications. Eur. J. Cancer 138, 149–155 (2020).
Vazquez-Castellanos, J. F., Biclot, A., Vrancken, G., Huys, G. R. & Raes, J. Design of synthetic microbial consortia for gut microbiota modulation. Curr. Opin. Pharmacol. 49, 52–59 (2019).
Cheng, A. G. et al. Design, construction, and in vivo augmentation of a complex gut microbiome. Cell 185, 3617–3636.e19 (2022).
Kelly, B. J., Kwon, J. H. & Woodworth, M. H. Escape velocity—the launch of microbiome therapies. J. Infect. Dis. 230, 2–4 (2024).
Terveer, E. M. et al. Human transmission of blastocystis by fecal microbiota transplantation without development of gastrointestinal symptoms in recipients. Clin. Infect. Dis. 71, 2630–2636 (2020).
Skelly, A. N., Sato, Y., Kearney, S. & Honda, K. Mining the microbiota for microbial and metabolite-based immunotherapies. Nat. Rev. Immunol. 19, 305–323 (2019).
Tanoue, T. et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 565, 600–605 (2019).
Spreafico, A. et al. First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO Trial). Ann. Oncol. 34, 520–530 (2023).
Oliva, I. G. et al. 607 MCGRAW trial: evaluation of the safety and efficacy of an oral microbiome intervention (SER-401) in combination with nivolumab in first line metastatic melanoma patients. J. Immunother. Cancer https://doi.org/10.1136/jitc-2022-SITC2022.0607 (2022).
Kang, X., Lau, H. C.-H. & Yu, J. Modulating gut microbiome in cancer immunotherapy: harnessing microbes to enhance treatment efficacy. Cell Rep. Med. 5, 101478 (2024).
Glitza, I. C. et al. Randomized placebo-controlled, biomarker-stratified phase Ib microbiome modulation in melanoma: impact of antibiotic preconditioning on microbiome and immunity. Cancer Discov. 14, 1161–1175 (2024).
Derosa, L. et al. Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients. Eur. Urol. 78, 195–206 (2020).
McCulloch, J. A. et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat. Med. 28, 545–556 (2022).
Andrews, M. C. et al. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat. Med. 27, 1432–1441 (2021).
Ramoneda, J., Jensen, T. B. N., Price, M. N., Casamayor, E. O. & Fierer, N. Taxonomic and environmental distribution of bacterial amino acid auxotrophies. Nat. Commun. 14, 7608 (2023).
Gould, A. L. et al. Microbiome interactions shape host fitness. Proc. Natl Acad. Sci. USA 115, E11951–E11960 (2018).
Van Der Lelie, D. et al. Rationally designed bacterial consortia to treat chronic immune-mediated colitis and restore intestinal homeostasis. Nat. Commun. 12, 3015 (2021).
Magnusdottir, S. et al. Generation of genome-scale metabolic reconstructions for 773 members of the human gut microbiota. Nat. Biotechnol. 35, 81–89 (2017).
Zelezniak, A. et al. Metabolic dependencies drive species co-occurrence in diverse microbial communities. Proc. Natl Acad. Sci. USA 112, 6449–6454 (2015).
Kost, C., Patil, K. R., Friedman, J., Garcia, S. L. & Ralser, M. Metabolic exchanges are ubiquitous in natural microbial communities. Nat. Microbiol. 8, 2244–2252 (2023).
Derosa, L. et al. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome. Cell 187, 3373–3389.e16 (2024).
Derosa, L. et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat. Med. 28, 315–324 (2022).
Liu, R. et al. Gut microbial structural variation associates with immune checkpoint inhibitor response. Nat. Commun. 14, 7421 (2023).
Zhang, H. et al. The cyanobacterial ornithine–ammonia cycle involves an arginine dihydrolase. Nat. Chem. Biol. 14, 575–581 (2018).
Gabrielli, N. et al. Unravelling metabolic cross-feeding in a yeast–bacteria community using 13C-based proteomics. Mol. Syst. Biol. 19, e11501 (2023).
Mager, L. F. et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 369, 1481–1489 (2020).
Zmora, N. et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell 174, 1388–1405.e21 (2018).
Zeevi, D. et al. Personalized nutrition by prediction of glycemic responses. Cell 163, 1079–1094 (2015).
Liu, H. et al. Ecological dynamics of the gut microbiome in response to dietary fiber. ISME J. 16, 2040–2055 (2022).
Randall, D. W. et al. Batch effect exerts a bigger influence on the rat urinary metabolome and gut microbiota than uraemia: a cautionary tale. Microbiome 7, 127 (2019).
Buckel, W. Energy conservation in fermentations of anaerobic bacteria. Front. Microbiol. 12, 703525 (2021).
Pedley, A. M. & Benkovic, S. J. A new view into the regulation of purine metabolism: the purinosome. Trends Biochem. Sci. 42, 141–154 (2017).
He, Y. et al. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity. Cell Metab. 33, 988–1000.e7 (2021).
Suez, J. et al. Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance. Cell 185, 3307–3328.e19 (2022).
Afrizal, A. et al. Enhanced cultured diversity of the mouse gut microbiota enables custom-made synthetic communities. Cell Host Microbe 30, 1630–1645.e25 (2022).
Xin, W. et al. Root microbiota of tea plants regulate nitrogen homeostasis and theanine synthesis to influence tea quality. Curr. Biol. 34, 868–880.e6 (2024).
Heras-Murillo, I., Adán-Barrientos, I., Galán, M., Wculek, S. K. & Sancho, D. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat. Rev. Clin. Oncol. 21, 257–277 (2024).
Garris, C. S. et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-gamma and IL-12. Immunity 49, 1148–1161.e7 (2018).
Luu, M. et al. Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer. Nat. Commun. 12, 4077 (2021).
Wang, T. et al. Inosine is an alternative carbon source for CD8+ T cell function under glucose restriction. Nat. Metab. 2, 635–647 (2020).
Poyet, M. et al. A library of human gut bacterial isolates paired with longitudinal multiomics data enables mechanistic microbiome research. Nat. Med. 25, 1442–1452 (2019).
Soto-Martin, E. C. et al. Vitamin biosynthesis by human gut butyrate-producing bacteria and cross-feeding in synthetic microbial communities. mBio 11, e00886–00820 (2020).
Desai, M. S. et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell 167, 1339–1353.e21 (2016).
Watson, A. R. et al. Metabolic independence drives gut microbial colonization and resilience in health and disease. Genome Biol. 24, 78 (2023).
Han, Y. et al. scRNA-seq profiling of neonatal and adult thymus-derived CD4+ T cells by a T cell origin-time tracing model. J. Mol. Cell. Biol. 14, mjac072 (2022).
Zeng, X. et al. Gut bacterial nutrient preferences quantified in vivo. Cell 185, 3441–3456.e19 (2022).
Han, S. et al. A metabolomics pipeline for the mechanistic interrogation of the gut microbiome. Nature 595, 415–420 (2021).
Xi, H. et al. A bacterial spermidine biosynthetic pathway via carboxyaminopropylagmatine. Sci. Adv. 9, eadj9075 (2023).
Han, J., Lin, K., Sequeira, C. & Borchers, C. H. An isotope-labeled chemical derivatization method for the quantitation of short-chain fatty acids in human feces by liquid chromatography-tandem mass spectrometry. Anal. Chim. Acta 854, 86–94 (2015).
Zhou, H. et al. A clinic responder-derived defined microbial consortium enhances anti-PD-1 immunotherapy efficacy in mice. Zenodo https://doi.org/10.5281/zenodo.18265182 (2026).
Read more about this post…
Credits: Source
Disclaimer
Coordinator, Faculty Affairs – Open Positions
Tarrant County College District (District, TX)
Read more about his post…
Credits: Source
Disclaimer
Biodegradable targeted polymeric mRNA nanoparticles enable in vivo CD19 CAR T cell generation and lead to B cell depletion – Research
While chimeric antigen receptor (CAR) T cell therapies have demonstrated therapeutic efficacy against B cell malignancies, widespread implementation of these therapies is hindered by a cumbersome, ex vivo manufacturing process. Delivery of CAR-encoding messenger RNA (mRNA) to endogenous T cells can generate these therapeutic cells in vivo and streamline this manufacturing workflow. To accomplish this, T cell-activating ligands were conjugated to a biodegradable polymeric mRNA nanoparticle to form T cell-targeted particles. By conjugating multiple activating ligands, T cell transfection and stimulation in vitro was increased, and greater T cell transfection and selectivity in vivo was achieved compared to an untargeted particle. These nanoparticles can flexibly encapsulate mRNA cargos and were used to deliver anti-CD19 CAR mRNA in vivo, enabling depletion of 95% of B cells in the peripheral blood and 50% depletion of splenic B cells in healthy mice. These findings regarding nanoparticle tropism and their potential therapeutic efficacy highlight the importance of this nonviral, polymeric platform to address key limitations associated with current CAR T practices.
Read more about this post…
Credits: Source
Disclaimer
Serving 